ClinicalTrials.gg
TerminatedNCT04173273CULTIVATEUpdated Jul 1, 2026Results posted

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

A Phase 2/3 interventional study of Etrasimod and Etrasimod in Crohn's Disease, sponsored by Pfizer. Terminated at 510 sites in 41 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Why this study was terminated
The study was prematurely discontinued due to a lack of efficacy in sub-study 1

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
379
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Crohn Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Crohn Disease · Pfizer.

Enrollment
Largest of 11
379 · median 180
Started
2020
the only one that year
Phase 2/3
Only one
of the 17
Registered
16th of 17
by date

Among the 17 studies in Crohn Disease by Pfizer, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2020, is the only one in phase 2/3, and was the 16th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 17 studies in Crohn Disease by Pfizer is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Crohn Disease by Pfizer as a file.
02

Study summary

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Extension or Maintenance, and Long-term Extension Periods), and the 4-Week Follow-Up Period for safety assessment.

Read the detailed description

This study includes 5 substudies:

Substudy A - Phase 2: A Phase 2, randomized, double-blind, substudy to assess the safety, tolerability, and efficacy of oral etrasimod therapy in participants with moderate to severe CD that supports the selection of an induction and maintenance dose(s) for Phase 3.

Substudy 1 - Phase 2: A Phase 2b randomized, double-blind, placebo-controlled, dose-ranging induction substudy to evaluate etrasimod as induction therapy and select an induction and maintenance dose(s) for continued evaluation in Phase 3.

Substudy 2 - Induction: A Phase 3 randomized, double-blind, placebo-controlled substudy to evaluate etrasimod as induction therapy.

Substudy 3 - Maintenance: A Phase 3 randomized, double-blind, placebo-controlled substudy to evaluate etrasimod as maintenance therapy. Participants from Substudy 1 and Substudy 2 will be enrolled in Substudy 3.

Substudy 4 - Long-Term Extension: A long-term extension substudy for participants who complete at least 52 weeks of treatment. Participants from Substudy 3 and Substudy A are planned to be enrolled in Substudy 4.

03

Conditions studied

  • Crohn's Disease

Keywords

  • Etrasimod
  • Crohn's disease
  • APD334
  • Inflammatory bowel disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility criteria applicable to all substudies:

Inclusion Criteria:

  • Men or women 18 to 80 years of age,
  • Ability to provide written or assent and to be compliant with the schedule of protocol assessments
  • Diagnosed with Crohn's disease (CD) ≥ 3 months
  • Have moderately to severely active CD at Screening
  • Demonstrated inadequate response (ie, primary non-response), loss of response to, or intolerance to ≥ 1 of the following therapies for the treatment of CD:

    1. Oral (eg, prednisone or its equivalent, budesonide)
    2. (eg, azathioprine [AZA], 6 mercaptopurine [6-MP], or methotrexate [MTX])
    3. Tumor necrosis factor alpha (TNFα) antagonists (eg, infliximab, adalimumab, certolizumab pegol, or biosimilars)
    4. Integrin receptor antagonist (eg, vedolizumab)
    5. Interleukin -12/-23 antagonist (eg, ustekinumab)
  • Females of must be nonpregnant
  • Females of childbearing potential and males must use

Exclusion Criteria:

  • History of inadequate response (ie, primary non-response) to agents from ≥ 2 classes of biologics marketed for the treatment of CD (ie, TNFα antagonists, interleukin 12/ 23 antagonist, and integrin receptor antagonist).
  • Have ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, diverticular disease associated colitis, toxic megacolon, or active infectious colitis or test positive for Clostridioides difficile toxin at Screening.
  • Have functional or post-operative short-bowel syndrome or any associated complications that may require surgery or interfere with efficacy assessments
  • Had surgical treatment for intra abdominal abscesses ≤ 8 weeks prior to randomization or surgical treatment for perianal abscesses ≤ 4 weeks prior to randomization.
  • Had intestinal resection ≤ 24 weeks prior to randomization or other intra abdominal surgeries ≤ 12 weeks prior to randomization.
  • Have an ileostomy or a colostomy.

Inclusion Criteria for Substudy 3:

- Participants who entered the Extended Induction Period of Substudy 1 and Substudy 2 must have completed the Extended Induction -Week 6 Visit

Inclusion Criteria for Substudy 4:

- Participant must have completed the Week 52 Visit of Substudy 3 or the Week 66 Visit of Substudy A

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
379 participants (actual)

Study arms

  • Experimental
    Etrasimod Dose A

    Drug: Etrasimod

  • Experimental
    Etrasimod Dose B

    Drug: Etrasimod

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Dose A taken by mouth, once daily.

    Also known as: APD334

  • Dose B taken by mouth, once daily.

    Also known as: APD334

  • DrugPlacebo

    Etrasimod matching placebo tablet taken by mouth, once daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA

    Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from study baseline in SES-CD. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.

    Time frame: Week 14 of SSA

  2. Percentage of Participants With Endoscopic Response by SES-CD at Week 14: SS1

    Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from study baseline in SES-CD. SES-CD consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple can be passed, 3= cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. Multiple imputation (MI) method used; percentage calculated based on average response rate from MI datasets.

    Time frame: Week 14 of SS1

  3. Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort

    Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); hematocrit (HCT): 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

    Time frame: Week 52 of study

  4. Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort

    Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

    Time frame: Week 52 of study

  5. Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort

    Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%,2= 50%-75%,3= \>75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.

    Time frame: Week 52 of study

  6. Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort

    Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right, transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%,2= 50%-75%,3= \>75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.

    Time frame: Week 52 of study

Secondary outcomes

  1. Percentage of Participants With Clinical Remission by CDAI at Week 14: SSA

    Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

    Time frame: Week 14 of SSA

  2. Change From Baseline in SES-CD Score at Week 14: SSA

    SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA

  3. Change From Baseline in CDAI Score at Week 14: SSA

    CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA

  4. Plasma Concentration of Etrasimod at 4 Hours Post-dose: SSA

    The plasma concentration of etrasimod at 4 hours post-dose has been reported in this outcome measure.

    Time frame: 4 hours post-dose on Day 1

  5. Steady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA

    The average steady-state Ctrough for Week 2 through 14 was calculated based on individual Ctrough data from Week 2, Week 6 and Week 14.

    Time frame: From Week 2 to Week 14

  6. Change From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA

  7. Percent Change From Baseline in ALC at Week 14 in Induction Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA

  8. Change From Baseline in ALC at Week 66 in Extension Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA

  9. Percent Change From Baseline in ALC at Week 66 in Extension Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA

  10. Change From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA

  11. Percent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA

  12. Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA

  13. Percent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA

  14. Change From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA

  15. Percent Change From Baseline in CRP at Week 14 in Induction Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA

  16. Change From Baseline in CRP at Week 66 in Extension Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA

  17. Percent Change From Baseline in CRP at Week 66 in Extension Period: SSA

    Time frame: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA

  18. Percentage of Participants With Clinical Remission by CDAI at Week 14: SS1

    Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. MI method was used; percentage was calculated based on average response rate from MI datasets.

    Time frame: Week 14 of SS1

  19. Percentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS1

    Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. MI method was used; percentage was calculated based on average response rate from MI datasets.

    Time frame: Week 14 of SS1

  20. Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort

    Clinical remission was CDAI score \<150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Week 52 of study

  21. Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort

    Clinical remission was CDAI score \<150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Week 52 of study

  22. Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort

    Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= \<10%, 2= 10%-30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50%-75%,3= \>75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.

    Time frame: Week 52 of study

  23. Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Non-Responder Cohort

    Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= \<10%, 2= 10%-30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50%-75%,3= \>75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.

    Time frame: Week 52 of study

  24. Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort

    Corticosteroid-free remission: CDAI score \<150 without receiving corticosteroids for \>=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores\*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Week 52 of study

  25. Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort

    Corticosteroid-free remission: CDAI score \<150 without receiving corticosteroids for \>=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores\*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Week 52 of study

  26. Percentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort

    Endoscopic remission: SES-CD score \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.

    Time frame: Week 52 of study

  27. Percentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort

    Endoscopic remission: SES-CD score \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.

    Time frame: Week 52 of study

  28. Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort

    Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.

    Time frame: Week 52 of study

  29. Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort

    Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.

    Time frame: Week 52 of study

  30. Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort

    Clinical response: clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.

    Time frame: Week 52 of study

  31. Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort

    Clinical response: clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.

    Time frame: Week 52 of study

  32. Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort

    CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 20, 28, 36, 44, 52

  33. Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort

    CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 20, 28, 36, 44, 52

  34. Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort

    Clinical Response was clinical remission by CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Week 52 of study

  35. Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort

    Clinical Response was clinical remission by CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Week 52 of study

  36. Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Responder Cohort

    The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 28 and 52

  37. Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Non-Responder Cohort

    The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 28 and 52

  38. Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Weeks 28 and 52: SS3 Responder Cohort

    The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 28 and 52

  39. Change From Baseline in IBDQ at Weeks 28 and 52: SS3 Non-Responder Cohort

    The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 28 and 52

  40. Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) at Weeks 28 and 52: SS3 Responder Cohort

    The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores mental (MCS) and physical (PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 28 and 52

  41. Change From Baseline in SF-36 at Weeks 28 and 52: SS3 Non-Responder Cohort

    The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores MCS and PCS. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 28 and 52

  42. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 28 and 52: SS3 Responder Cohort

    The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 28 and 52

  43. Change From Baseline in FACIT-F at Weeks 28 and 52: SS3 Non-Responder Cohort

    The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 28 and 52

  44. Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort

    Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Week 52 of study

  45. Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort

    Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Week 52 of study

  46. Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort

    The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 20, 28, 36, 44 and 52

  47. Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort

    The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline, study Weeks 20, 28, 36, 44 and 52

  48. Time to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort

    Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score \<8. Normalization of FCP was defined as FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.

    Time frame: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)

  49. Time to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort

    Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score \<8. Normalization of FCP was defined as FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.

    Time frame: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)

  50. Time to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort

    Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or \>= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score \<8. Normalization of FCP: FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.

    Time frame: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)

  51. Time to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort

    Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or \>= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score \<8. Normalization of FCP: FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.

    Time frame: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)

  52. Change From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort

    SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0=unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline and Week 52 of study

  53. Change From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort

    SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0=unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

    Time frame: Baseline and Week 52 of study

  54. Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort

    Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.

    Time frame: Week 52 of study

  55. Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort

    Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.

    Time frame: Week 52 of study

  56. Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort

    Endoscopic remission: SES-CD \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.

    Time frame: Week 52 of study

  57. Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort

    Endoscopic remission: SES-CD \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.

    Time frame: Week 52 of study

  58. Number of Participants According to Markedly Abnormal Criteria for Electrocardiogram (ECG) Parameters: SS4

    Pre-defined markedly abnormal criteria for ECG parameters included: QT interval: \>500 (milliseconds \[msec\]); change from SS4 baseline \>30 msec and change from SS4 baseline \>60 msec. QT interval corrected using Fridericia's formula (QTcF) (msec): \>=450 (male) or \>=470 (female) msec; change from SS4 baseline \>30 msec; change from SS4 baseline \>60 msec. PR interval (msec): \>230 msec. Only those ECG parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 Baseline was defined as the last non-missing measurement taken up to the date of first dose in the SS4.

    Time frame: Baseline, Weeks 52, and 104 of SS4

  59. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs by Severity and Treatment Related TEAEs: SS3

    AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, Grade(G) 1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.

    Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)

  60. Number of Participants With TEAEs of Special Interest: SS3

    The TEAEs of special interest included: cardiovascular events (bradycardia, atrioventricular \[AV\] conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction \[forced expiratory volume in 1 second, and forced vital capacity\], decreased gas exchange \[diffusing capacity of the lung for carbon monoxide\]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.

    Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)

  61. Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS3

    Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \>1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.

    Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)

  62. Number of Participants With TEAEs, SAEs, TEAEs by Severity and Treatment Related TEAEs: SS4

    AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, G1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.

    Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)

  63. Number of Participants With TEAEs of Special Interest: SS4

    The TEAEs of special interest included: cardiovascular events (bradycardia, AV conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction \[forced expiratory volume in 1 second, and forced vital capacity\], decreased gas exchange \[diffusing capacity of the lung for carbon monoxide\]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.

    Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)

  64. Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS4

    Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \>1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.

    Time frame: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)

  65. Number of Participants According to Markedly Abnormal Criteria for Vital Signs: SS4

    Pre-defined markedly abnormal criteria for vital signs included: Systolic blood pressure (millimeters of mercury \[mmHg\]): low: \<=90 mmHg and high: \>150 mmHg. Diastolic blood pressure (mmHg): low: \<=50 mmHg and high: \>90 mmHg. Heart rate (beats per minute \[bpm\]): low: \<40 bpm, \<50 bpm and high: \>100 bpm. Only those vital signs parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 baseline=the last non-missing measurement taken up to the date of first dose in the SS4.

    Time frame: Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4

  66. Percentage of Participants With Clinical Remission by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4

    Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

    Time frame: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4

  67. Percentage of Participants With Clinical Response by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4

    Clinical Response was defined as having clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission was considered as CDAI \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

    Time frame: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4

  68. Percentage of Participants With Clinical Remission by PRO2 at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4

    Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.

    Time frame: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4

07

Results

Posted Jul 1, 2026
Limitations and caveats
Participants from "SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period" did not have the Week 66 assessment for ALC, FCP, and CRP; hence, no participants were analyzed for the mentioned arm at Week 66.

Participant flow

379 participants (84 in sub-study A \[SSA\]; 295 in SS1) enrolled. Participants who completed treatment and met study specific criteria in SS1 eligible for SS3. Participants from SS3 and SSA who completed at least 52 and 66 weeks of treatment, respectively eligible for SS4. Sub-studies planned: SSA, SS1, SS2, SS3 and SS4. The study (including SS3 and SS4) terminated early due to insufficient induction treatment benefit of etrasimod as observed in SS1. SS2 not initiated; its results not reported.

SSA: Induction Period
Participant flow — SSA: Induction Period
MilestoneSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Started1424100000000000000000000
Completed1323600000000000000000000
Not completed010500000000000000000000
Withdrew: Adverse event02200000000000000000000
Withdrew: Withdrawal by subject04200000000000000000000
Withdrew: Physician decision01100000000000000000000
Withdrew: Lost to follow-up01000000000000000000000
Withdrew: Disease worsening01000000000000000000000
Withdrew: Other01000000000000000000000
SSA: Extension Period
Participant flow — SSA: Extension Period
MilestoneSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Started0001282340000000000000000
Completed0001151210000000000000000
Not completed0000131130000000000000000
Withdrew: Adverse event00003060000000000000000
Withdrew: Withdrawal by subject00005120000000000000000
Withdrew: Physician decision00003010000000000000000
Withdrew: Lost to follow-up00000010000000000000000
Withdrew: Disease worsening00002020000000000000000
Withdrew: Other00000010000000000000000
SS1: Induction Period
Participant flow — SS1: Induction Period
MilestoneSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Started000000010098970000000000000
Completed00000008789810000000000000
Not completed0000000139160000000000000
Withdrew: Adverse event00000007570000000000000
Withdrew: Withdrawal by subject00000003430000000000000
Withdrew: Disease worsening00000002050000000000000
Withdrew: Other00000001000000000000000
Withdrew: Lost to follow-up00000000010000000000000
SS1: Extended Induction Period
Participant flow — SS1: Extended Induction Period
MilestoneSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Started000000000017183736000000000
Completed000000000015153333000000000
Not completed00000000002343000000000
Withdrew: Adverse event00000000000121000000000
Withdrew: Withdrawal by subject00000000000201000000000
Withdrew: Lost to follow-up00000000000010000000000
Withdrew: Disease worsening00000000002011000000000
SS3
Participant flow — SS3
MilestoneSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Started000000000000004738332835151200
Completed0000000000000027291917213600
Not completed0000000000000020914111412600
Withdrew: Adverse event00000000000000332132100
Withdrew: Withdrawal by subject00000000000000503424100
Withdrew: Physician decision00000000000000001121200
Withdrew: Site termination by sponsor00000000000000844474100
Withdrew: Disease worsening00000000000000414100100
Withdrew: Other00000000000000010001000
SS4
Participant flow — SS4
MilestoneSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Started0000000000000000000007271
Completed00000000000000000000000
Not completed0000000000000000000007271
Withdrew: Adverse event00000000000000000000066
Withdrew: Withdrawal by subject00000000000000000000095
Withdrew: Physician decision00000000000000000000013
Withdrew: Site termination by sponsor0000000000000000000005052
Withdrew: Disease worsening00000000000000000000014
Withdrew: Death00000000000000000000010
Withdrew: Pregnancy00000000000000000000010
Withdrew: Other00000000000000000000031

Outcome measures

PrimaryPercentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA

Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from study baseline in SES-CD. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.

Time frame:
Week 14 of SSA
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA
Percentage of participantsSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSANA (NA to NA)21.4 (11.7 to 34.4)12.2 (4.9 to 23.9)
PrimaryPercentage of Participants With Endoscopic Response by SES-CD at Week 14: SS1

Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from study baseline in SES-CD. SES-CD consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple can be passed, 3= cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. Multiple imputation (MI) method used; percentage calculated based on average response rate from MI datasets.

Time frame:
Week 14 of SS1
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Response by SES-CD at Week 14: SS1
Percentage of participantsSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction Period
Percentage of Participants With Endoscopic Response by SES-CD at Week 14: SS114.9 (8.8 to 20.9)17.3 (10.9 to 23.8)14.9 (8.9 to 21.0)
Statistical analysis
  • SS1: Placebo in Induction Period vs SS1: Etrasimod 2 mg in Induction Period · Mantel Haenszel · p = =0.3147 · Percentage difference: 2.5 · 90% CI -6.1 to 11.1
  • SS1: Placebo in Induction Period vs SS1: Etrasimod 3 mg in Induction Period · Mantel Haenszel · p = =0.4857 · Percentage difference: 0.2 · 90% CI -8.3 to 8.7
PrimaryPercentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort

Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); hematocrit (HCT): 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort36.4 (17.2 to 59.3)69.6 (47.1 to 86.8)50.0 (21.1 to 78.9)87.5 (61.7 to 98.4)73.3 (44.9 to 92.2)
PrimaryPercentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort

Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort0 (0.0 to 70.8)60.0 (14.7 to 94.7)
PrimaryPercentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort

Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%,2= 50%-75%,3= \>75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort12.5 (2.7 to 32.4)24.0 (9.4 to 45.1)10.0 (0.3 to 44.5)13.3 (1.7 to 40.5)13.3 (1.7 to 40.5)
PrimaryPercentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort

Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right, transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%,2= 50%-75%,3= \>75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort0 (0.0 to 84.2)16.7 (0.4 to 64.1)
SecondaryPercentage of Participants With Clinical Remission by CDAI at Week 14: SSA

Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

Time frame:
Week 14 of SSA
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by CDAI at Week 14: SSA
Percentage of participantsSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Percentage of Participants With Clinical Remission by CDAI at Week 14: SSANA (NA to NA)31.0 (19.4 to 44.6)41.5 (28.4 to 55.5)
SecondaryChange From Baseline in SES-CD Score at Week 14: SSA

SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.

Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Reported as:
Mean · Units on a scale
Change From Baseline in SES-CD Score at Week 14: SSA
Units on a scaleSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Change From Baseline in SES-CD Score at Week 14: SSANA ± NA-1.1 ± 6.63-0.9 ± 5.53
SecondaryChange From Baseline in CDAI Score at Week 14: SSA

CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Reported as:
Mean · Units on a scale
Change From Baseline in CDAI Score at Week 14: SSA
Units on a scaleSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Change From Baseline in CDAI Score at Week 14: SSANA ± NA-179.7 ± 92.80-136.4 ± 106.38
SecondaryPlasma Concentration of Etrasimod at 4 Hours Post-dose: SSA

The plasma concentration of etrasimod at 4 hours post-dose has been reported in this outcome measure.

Time frame:
4 hours post-dose on Day 1
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration of Etrasimod at 4 Hours Post-dose: SSA
Nanogram per milliliterSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Plasma Concentration of Etrasimod at 4 Hours Post-dose: SSA36.32 ± 34.5237.16 ± 32.06
SecondarySteady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA

The average steady-state Ctrough for Week 2 through 14 was calculated based on individual Ctrough data from Week 2, Week 6 and Week 14.

Time frame:
From Week 2 to Week 14
Reported as:
Geometric mean · Nanogram per milliliter
Steady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA
Nanogram per milliliterSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Steady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA59.63 ± 42.8982.28 ± 31.38
SecondaryChange From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Reported as:
Mean · 10^9 cells per liter
Change From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSA
10^9 cells per literSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Change From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSANA ± NA-1.271 ± 0.7905-0.921 ± 0.3825
SecondaryPercent Change From Baseline in ALC at Week 14 in Induction Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Reported as:
Mean · Percent change
Percent Change From Baseline in ALC at Week 14 in Induction Period: SSA
Percent changeSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Percent Change From Baseline in ALC at Week 14 in Induction Period: SSANA ± NA-60.223 ± 22.7486-63.121 ± 13.1499
SecondaryChange From Baseline in ALC at Week 66 in Extension Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Reported as:
Mean · 10^9 cells per liter
Change From Baseline in ALC at Week 66 in Extension Period: SSA
10^9 cells per literSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period
Change From Baseline in ALC at Week 66 in Extension Period: SSANA ± NA-1.648 ± 1.1529—-0.931 ± 0.4374
SecondaryPercent Change From Baseline in ALC at Week 66 in Extension Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Reported as:
Mean · Percent change
Percent Change From Baseline in ALC at Week 66 in Extension Period: SSA
Percent changeSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period
Percent Change From Baseline in ALC at Week 66 in Extension Period: SSANA ± NA-71.174 ± 10.4559—-60.988 ± 15.2935
SecondaryChange From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Reported as:
Mean · Microgram per milligram
Change From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSA
Microgram per milligramSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Change From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSANA ± NA-19.170 ± 2557.1902-1542.684 ± 6282.4409
SecondaryPercent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Reported as:
Mean · Percent change
Percent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSA
Percent changeSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Percent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSANA ± NA349.591 ± 1556.0649209.156 ± 816.9889
SecondaryChange From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Reported as:
Mean · Microgram per milligram
Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Microgram per milligramSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period
Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSANA ± NA-927.343 ± 915.5152—-297.345 ± 982.0333
SecondaryPercent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Reported as:
Mean · Percent change
Percent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Percent changeSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period
Percent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSANA ± NA-9.613 ± 103.7985—296.823 ± 812.1047
SecondaryChange From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Reported as:
Mean · Milligram per liter
Change From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSA
Milligram per literSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Change From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSANA ± NA-3.037 ± 22.6182-1.459 ± 11.9907
SecondaryPercent Change From Baseline in CRP at Week 14 in Induction Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Reported as:
Mean · Percent change
Percent Change From Baseline in CRP at Week 14 in Induction Period: SSA
Percent changeSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction Period
Percent Change From Baseline in CRP at Week 14 in Induction Period: SSANA ± NA93.609 ± 232.527685.476 ± 345.5674
SecondaryChange From Baseline in CRP at Week 66 in Extension Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Reported as:
Mean · Milligram per liter
Change From Baseline in CRP at Week 66 in Extension Period: SSA
Milligram per literSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period
Change From Baseline in CRP at Week 66 in Extension Period: SSANA ± NA-4.282 ± 21.9909—-3.474 ± 25.6826
SecondaryPercent Change From Baseline in CRP at Week 66 in Extension Period: SSA
Time frame:
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Reported as:
Mean · Percent change
Percent Change From Baseline in CRP at Week 66 in Extension Period: SSA
Percent changeSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period
Percent Change From Baseline in CRP at Week 66 in Extension Period: SSANA ± NA-8.856 ± 79.2428—611.474 ± 1388.2642
SecondaryPercentage of Participants With Clinical Remission by CDAI at Week 14: SS1

Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. MI method was used; percentage was calculated based on average response rate from MI datasets.

Time frame:
Week 14 of SS1
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by CDAI at Week 14: SS1
Percentage of participantsSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction Period
Percentage of Participants With Clinical Remission by CDAI at Week 14: SS132.0 (24.1 to 39.8)29.3 (21.4 to 37.1)36.5 (28.3 to 44.7)
Statistical analysis
  • SS1: Placebo in Induction Period vs SS1: Etrasimod 2 mg in Induction Period · Mantel Haenszel · p = =0.6597 · Percentage difference: -2.7 · 90% CI -13.5 to 8.1
  • SS1: Placebo in Induction Period vs SS1: Etrasimod 3 mg in Induction Period · Mantel Haenszel · p = =0.2313 · Percentage difference: 4.9 · 90% CI -6.1 to 15.8
SecondaryPercentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS1

Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. MI method was used; percentage was calculated based on average response rate from MI datasets.

Time frame:
Week 14 of SS1
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS1
Percentage of participantsSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction Period
Percentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS116.2 (10.1 to 22.2)27.6 (19.8 to 35.3)28.8 (21.0 to 36.6)
Statistical analysis
  • SS1: Placebo in Induction Period vs SS1: Etrasimod 2 mg in Induction Period · Mantel Haenszel · p = =0.0267 · Percentage difference: 11.4 · 90% CI 1.7 to 21.1
  • SS1: Placebo in Induction Period vs SS1: Etrasimod 3 mg in Induction Period · Mantel Haenszel · p = =0.0140 · Percentage difference: 12.9 · 90% CI 3.2 to 22.5
SecondaryPercentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort

Clinical remission was CDAI score \<150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort38.5 (13.9 to 68.4)92.9 (66.1 to 99.8)50.0 (11.8 to 88.2)90.9 (58.7 to 99.8)100.0 (63.1 to 100.0)
SecondaryPercentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort

Clinical remission was CDAI score \<150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort—100.0 (2.5 to 100.0)
SecondaryPercentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort

Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= \<10%, 2= 10%-30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50%-75%,3= \>75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort60.0 (14.7 to 94.7)57.1 (18.4 to 90.1)50.0 (1.3 to 98.7)50.0 (6.8 to 93.2)50.0 (1.3 to 98.7)
SecondaryPercentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Non-Responder Cohort

Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= \<10%, 2= 10%-30%, 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50%-75%,3= \>75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.

Time frame:
Week 52 of study

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort

Corticosteroid-free remission: CDAI score \<150 without receiving corticosteroids for \>=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores\*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort28.6 (3.7 to 71.0)66.7 (22.3 to 95.7)0 (0.0 to 97.5)60.0 (14.7 to 94.7)66.7 (9.4 to 99.2)
SecondaryPercentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort

Corticosteroid-free remission: CDAI score \<150 without receiving corticosteroids for \>=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores\*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort—100.0 (2.5 to 100.0)
SecondaryPercentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort

Endoscopic remission: SES-CD score \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort0 (0.0 to 14.2)0 (0.0 to 13.7)0 (0.0 to 30.8)0 (0.0 to 21.8)0 (0.0 to 21.8)
SecondaryPercentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort

Endoscopic remission: SES-CD score \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0= unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort0 (0.0 to 84.2)0 (0.0 to 45.9)
SecondaryPercentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort

Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort27.3 (10.7 to 50.2)60.9 (38.5 to 80.3)50.0 (21.1 to 78.9)62.5 (35.4 to 84.8)40.0 (16.3 to 67.7)
SecondaryPercentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort

Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort0 (0.0 to 70.8)40.0 (5.3 to 85.3)
SecondaryPercentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort

Clinical response: clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort70.8 (48.9 to 87.4)84.0 (63.9 to 95.5)66.7 (34.9 to 90.1)93.8 (69.8 to 99.8)75.0 (47.6 to 92.7)
SecondaryPercentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort

Clinical response: clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort0 (0.0 to 70.8)50.0 (11.8 to 88.2)
SecondaryChange From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort

CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 20, 28, 36, 44, 52
Reported as:
Mean · Units on a scale
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
Units on a scaleSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Week 2022.8 ± 110.65-7.8 ± 85.2329.6 ± 116.3612.3 ± 64.57-6.8 ± 74.34
Week 28-5.1 ± 77.47-33.3 ± 56.262.5 ± 110.9416.9 ± 67.92-17.4 ± 57.51
Week 366.6 ± 86.81-9.1 ± 52.900.6 ± 111.7510.2 ± 65.61-14.0 ± 66.42
Week 446.0 ± 90.24-25.0 ± 77.0-24.0 ± 80.95-6.5 ± 56.14-4.3 ± 67.80
Week 527.2 ± 83.06-30.6 ± 65.99-17.6 ± 95.37-8.1 ± 60.53-7.2 ± 56.05
SecondaryChange From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort

CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 20, 28, 36, 44, 52
Reported as:
Mean · Units on a scale
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
Units on a scaleSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Week 20-13.9 ± 64.284.1 ± 71.53
Week 28-14.8 ± 49.59-24.8 ± 129.50
Week 36-7.7 ± 76.32-5.8 ± 56.78
Week 441.5 ± 94.92-30.7 ± 64.30
Week 5216.4 ± 39.97-37.1 ± 80.80
SecondaryPercentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort

Clinical Response was clinical remission by CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort75.0 (50.90 to 91.34)89.5 (66.86 to 98.70)66.7 (29.93 to 92.51)92.9 (66.13 to 99.82)100.0 (69.15 to 100.00)
SecondaryPercentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort

Clinical Response was clinical remission by CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI \<150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores\*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort—100.0 (2.50 to 100.00)
SecondaryChange From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Responder Cohort

The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 28 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Responder Cohort
Units on a scaleSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Systemic Symptoms: Week 28-0.2 ± 0.67-0.1 ± 0.410.0 ± 0.96-0.1 ± 0.47-0.3 ± 0.87
Systemic Symptoms: Week 52-0.3 ± 0.610.0 ± 0.540.0 ± 0.67-0.3 ± 0.60-0.5 ± 0.87
Coping Strategies: Week 28-0.4 ± 1.34-0.3 ± 1.19-0.3 ± 1.27-0.3 ± 1.08-0.2 ± 1.97
Coping Strategies: Week 52-0.5 ± 1.620.0 ± 1.54-0.2 ± 0.96-0.4 ± 1.08-0.4 ± 2.20
Daily Life Impact: Week 28-0.3 ± 0.79-0.2 ± 0.710.3 ± 0.95-0.1 ± 0.910.0 ± 0.96
Daily Life Impact: Week 520.0 ± 0.970.1 ± 0.820.6 ± 0.72-0.2 ± 0.96-0.5 ± 0.92
Emotional Impact: Week 280.0 ± 0.780.0 ± 0.720.2 ± 0.970.0 ± 0.66-0.1 ± 0.92
Emotional Impact: Week 52-0.1 ± 0.900.2 ± 0.710.4 ± 0.76-0.2 ± 0.53-0.5 ± 0.90
Bowel Signs and Symptoms: Week 28-0.2 ± 0.63-0.2 ± 0.660.0 ± 0.94-0.2 ± 0.80-0.3 ± 0.73
Bowel Signs and Symptoms: Week 52-0.3 ± 0.970.1 ± 0.710.2 ± 0.66-0.2 ± 0.99-0.5 ± 0.82
Functional Symptoms: Week 28-0.2 ± 0.71-0.1 ± 0.45-0.2 ± 0.940.1 ± 0.36-0.3 ± 0.74
Functional Symptoms: Week 52-0.3 ± 0.63-0.1 ± 0.48-0.1 ± 0.53-0.2 ± 0.44-0.7 ± 1.31
SecondaryChange From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Non-Responder Cohort

The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 28 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Non-Responder Cohort
Units on a scaleSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Systemic Symptoms: Week 280.0 ± 0.350.1 ± 0.43
Systemic Symptoms: Week 520.4 ± 0.560.0 ± 0.07
Coping Strategies: Week 280.0 ± 1.090.3 ± 0.52
Coping Strategies: Week 520.4 ± 2.490.1 ± 0.26
Daily Life Impact: Week 280.1 ± 0.710.0 ± 0.49
Daily Life Impact: Week 52-0.1 ± 0.750.1 ± 0.58
Emotional Impact: Week 28-0.1 ± 0.910.2 ± 0.31
Emotional Impact: Week 520.6 ± 1.150.1 ± 0.71
Bowel Signs and Symptoms: Week 28-0.3 ± 0.85-0.1 ± 1.22
Bowel Signs and Symptoms: Week 52-0.1 ± 1.29-0.2 ± 0.23
Functional Symptoms: Week 280.0 ± 0.280.1 ± 0.60
Functional Symptoms: Week 52-0.2 ± 0.12-0.4 ± 0.33
SecondaryChange From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Weeks 28 and 52: SS3 Responder Cohort

The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 28 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Weeks 28 and 52: SS3 Responder Cohort
Units on a scaleSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Week 282.7 ± 32.180.2 ± 22.67-5.4 ± 37.063.7 ± 31.22-3.2 ± 28.55
Week 52-0.9 ± 37.99-5.7 ± 32.07-12.1 ± 39.218.8 ± 32.790.6 ± 21.32
SecondaryChange From Baseline in IBDQ at Weeks 28 and 52: SS3 Non-Responder Cohort

The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 28 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in IBDQ at Weeks 28 and 52: SS3 Non-Responder Cohort
Units on a scaleSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Week 28-0.3 ± 32.45-4.9 ± 17.07
Week 521.5 ± 23.334.0 ± 15.26
SecondaryChange From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) at Weeks 28 and 52: SS3 Responder Cohort

The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores mental (MCS) and physical (PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 28 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) at Weeks 28 and 52: SS3 Responder Cohort
Units on a scaleSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Week 280.0 ± 0.110.0 ± 0.080.0 ± 0.120.0 ± 0.080.0 ± 0.12
Week 520.0 ± 0.150.0 ± 0.120.0 ± 0.070.0 ± 0.120.0 ± 0.09
SecondaryChange From Baseline in SF-36 at Weeks 28 and 52: SS3 Non-Responder Cohort

The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores MCS and PCS. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 28 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in SF-36 at Weeks 28 and 52: SS3 Non-Responder Cohort
Units on a scaleSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Week 280.0 ± 0.100.0 ± 0.06
Week 520.0 ± 0.190.0 ± 0.10
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 28 and 52: SS3 Responder Cohort

The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 28 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 28 and 52: SS3 Responder Cohort
Units on a scaleSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Week 280.3 ± 9.660.4 ± 10.07-3.4 ± 11.520.0 ± 9.540.7 ± 7.98
Week 52-1.9 ± 13.56-1.4 ± 8.94-1.8 ± 8.640.0 ± 12.831.7 ± 7.48
SecondaryChange From Baseline in FACIT-F at Weeks 28 and 52: SS3 Non-Responder Cohort

The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 28 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in FACIT-F at Weeks 28 and 52: SS3 Non-Responder Cohort
Units on a scaleSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Week 28-0.6 ± 12.32-0.3 ± 5.44
Week 52-3.0 ± 12.291.5 ± 2.07
SecondaryPercentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort

Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort66.7 (9.43 to 99.16)90.0 (55.50 to 99.75)60.0 (14.66 to 94.73)77.8 (39.99 to 97.19)71.4 (29.04 to 96.33)
SecondaryPercentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort

Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort—100.0 (2.50 to 100.00)
SecondaryChange From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort

The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
Units on a scaleSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Week 200.6 ± 2.830.2 ± 2.590.6 ± 2.440.1 ± 1.500.2 ± 2.27
Week 28-0.5 ± 1.84-0.6 ± 1.75-0.2 ± 2.160.2 ± 1.79-0.3 ± 1.26
Week 36-0.2 ± 2.12-0.1 ± 1.420.0 ± 2.860.0 ± 1.75-0.2 ± 1.60
Week 44-0.3 ± 1.72-0.4 ± 2.49-0.7 ± 1.97-0.1 ± 1.86-0.3 ± 1.79
Week 520.2 ± 1.72-0.5 ± 2.08-0.7 ± 2.27-0.2 ± 1.59-0.3 ± 1.47
SecondaryChange From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort

The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline, study Weeks 20, 28, 36, 44 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
Units on a scaleSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Week 200.2 ± 2.11-0.5 ± 2.48
Week 28-0.7 ± 1.80-1.6 ± 4.45
Week 36-0.7 ± 2.18-0.8 ± 1.22
Week 44-0.1 ± 3.52-1.3 ± 1.14
Week 520.1 ± 0.81-1.3 ± 1.31
SecondaryTime to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort

Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score \<8. Normalization of FCP was defined as FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.

Time frame:
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Reported as:
Mean · Days
Time to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort
DaysSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Time to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort189.7 ± 94.8200.1 ± 105.3153.5 ± 101.9161.2 ± 121.6154.1 ± 111.3
SecondaryTime to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort

Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score \<8. Normalization of FCP was defined as FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.

Time frame:
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Reported as:
Mean · Days
Time to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
DaysSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Time to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort158.7 ± 70.4157.7 ± 108.7
SecondaryTime to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort

Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or \>= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score \<8. Normalization of FCP: FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.

Time frame:
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Reported as:
Mean · Days
Time to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort
DaysSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Time to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort189.7 ± 94.8200.1 ± 105.3153.5 ± 101.9161.2 ± 121.6154.1 ± 111.3
SecondaryTime to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort

Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or \>= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score \<8. Normalization of FCP: FCP \<=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.

Time frame:
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Reported as:
Mean · Days
Time to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
DaysSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Time to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort158.7 ± 70.4152.7 ± 110.0
SecondaryChange From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort

SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0=unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline and Week 52 of study
Reported as:
Mean · Units on a scale
Change From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort
Units on a scaleSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Change From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort1.3 ± 5.98-0.3 ± 4.720.4 ± 5.680.6 ± 3.81-2.1 ± 5.94
SecondaryChange From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort

SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= \<10%, 2= 10% - 30% and 3= \>30%. Affected surface score: 0=unaffected segment, 1= \<50%, 2= 50% - 75%, and 3= \>75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.

Time frame:
Baseline and Week 52 of study
Reported as:
Mean · Units on a scale
Change From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort
Units on a scaleSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Change From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort8.5 ± 3.541.7 ± 4.37
SecondaryPercentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort

Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort0.0 (0.00 to 14.82)20.0 (6.83 to 40.70)0.0 (0.00 to 26.46)12.5 (1.55 to 38.35)0.0 (0.00 to 20.59)
SecondaryPercentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort

Endoscopic response: SES-CD score \<=4 and at least 2-point reduction from baseline with no subscore \>1 or \>=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort0.0 (0.00 to 70.76)0.0 (0.00 to 45.93)
SecondaryPercentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort

Endoscopic remission: SES-CD \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Percentage of participantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/Placebo
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort0.0 (0.00 to 14.25)0.0 (0.00 to 13.72)0.0 (0.00 to 26.46)0.0 (0.00 to 20.59)0.0 (0.00 to 20.59)
SecondaryPercentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort

Endoscopic remission: SES-CD \<=4 and at least 2-point reduction from baseline with no sub-score \>1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score \<8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.

Time frame:
Week 52 of study
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Percentage of participantsSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort0.0 (0.00 to 70.76)0.0 (0.00 to 45.93)
SecondaryNumber of Participants According to Markedly Abnormal Criteria for Electrocardiogram (ECG) Parameters: SS4

Pre-defined markedly abnormal criteria for ECG parameters included: QT interval: \>500 (milliseconds \[msec\]); change from SS4 baseline \>30 msec and change from SS4 baseline \>60 msec. QT interval corrected using Fridericia's formula (QTcF) (msec): \>=450 (male) or \>=470 (female) msec; change from SS4 baseline \>30 msec; change from SS4 baseline \>60 msec. PR interval (msec): \>230 msec. Only those ECG parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 Baseline was defined as the last non-missing measurement taken up to the date of first dose in the SS4.

Time frame:
Baseline, Weeks 52, and 104 of SS4
Reported as:
Count of participants · Participants
Number of Participants According to Markedly Abnormal Criteria for Electrocardiogram (ECG) Parameters: SS4
ParticipantsSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Baseline; QTcF Interval: >=450 (male) or >=470 (female) msec10
Week 52; QTcF Interval: >=450 (male) or >=470 (female) msec31
Week 52; QTcF Interval: change from baseline >30 msec21
Week 104; QTcF Interval: >=450 (male) or >=470 (female) msec11
Week 104; QTcF Interval: change from baseline >30 msec31
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs by Severity and Treatment Related TEAEs: SS3

AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, Grade(G) 1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.

Time frame:
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs by Severity and Treatment Related TEAEs: SS3
ParticipantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Participants with TEAE35302725232618
Participants with SAE2436454
Participants with Grade 1 TEAE111112101279
Participants with Grade 2 TEAE181410137155
Participants with Grade 3 TEAE6452444
Participants with Grade 4 TEAE0100000
Participants with Grade 5 TEAE0000000
Participants with Treatment Related TEAE41048286
SecondaryNumber of Participants With TEAEs of Special Interest: SS3

The TEAEs of special interest included: cardiovascular events (bradycardia, atrioventricular \[AV\] conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction \[forced expiratory volume in 1 second, and forced vital capacity\], decreased gas exchange \[diffusing capacity of the lung for carbon monoxide\]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.

Time frame:
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs of Special Interest: SS3
ParticipantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Number of Participants With TEAEs of Special Interest: SS30404215
SecondaryNumber of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS3

Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \>1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.

Time frame:
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS3
ParticipantsSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mg
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS30000000
SecondaryNumber of Participants With TEAEs, SAEs, TEAEs by Severity and Treatment Related TEAEs: SS4

AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, G1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.

Time frame:
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs, SAEs, TEAEs by Severity and Treatment Related TEAEs: SS4
ParticipantsSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Participants with TEAEs5655
Participants with SAEs108
Participants with Grade 1 AEs2125
Participants with Grade 2 AEs1823
Participants with Grade 3 AEs156
Participants with Grade 4 AEs11
Participants with Grade 5 AEs10
Participants with Treatment Related AEs1722
SecondaryNumber of Participants With TEAEs of Special Interest: SS4

The TEAEs of special interest included: cardiovascular events (bradycardia, AV conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction \[forced expiratory volume in 1 second, and forced vital capacity\], decreased gas exchange \[diffusing capacity of the lung for carbon monoxide\]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.

Time frame:
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs of Special Interest: SS4
ParticipantsSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Number of Participants With TEAEs of Special Interest: SS485
SecondaryNumber of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS4

Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (\<0.8\*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration \<0.8\*LLN or \>1.5\*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (\>1.2\*ULN), Prothrombin Time(\>1.1\*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5\*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (\>3.0\*ULN); Albumin, Urate (\<0.8\*LLN and \>1.2\*ULN; Urea Nitrogen,Creatinine Cholesterol \>1.3\*ULN; Cholesterol \<0.8\*LLN or \>1.2\*LLN, Triglycerides,Potassium,Calcium \< 0.9x LLN \& \>1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite \>=1; Leukocyte Erythrocytes, Leukocytes \>=20; Epithelial Cells\>=6, Hyaline Cast\>1; Bacteria\>20. Number of participants with any laboratory abnormality meeting specified criteria is included.

Time frame:
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS4
ParticipantsSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS400
SecondaryNumber of Participants According to Markedly Abnormal Criteria for Vital Signs: SS4

Pre-defined markedly abnormal criteria for vital signs included: Systolic blood pressure (millimeters of mercury \[mmHg\]): low: \<=90 mmHg and high: \>150 mmHg. Diastolic blood pressure (mmHg): low: \<=50 mmHg and high: \>90 mmHg. Heart rate (beats per minute \[bpm\]): low: \<40 bpm, \<50 bpm and high: \>100 bpm. Only those vital signs parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 baseline=the last non-missing measurement taken up to the date of first dose in the SS4.

Time frame:
Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Reported as:
Count of participants · Participants
Number of Participants According to Markedly Abnormal Criteria for Vital Signs: SS4
ParticipantsSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Baseline; Systolic Blood Pressure: <=90 mmHg10
Baseline; Systolic Blood Pressure: >150 mmHg12
Baseline; Diastolic Blood Pressure: <=50 mmHg10
Baseline; Diastolic Blood Pressure: >90 mmHg67
Baseline; Heart Rate: >100 bpm10
Week 1; Diastolic Blood Pressure: <=50 mmHg20
Week 1; Diastolic Blood Pressure: >90 mmHg01
Week 12; Systolic Blood Pressure: >150 mmHg02
Week 12; Diastolic Blood Pressure: >90 mmHg59
Week 24; Systolic Blood Pressure: <=90 mmHg10
Week 24; Systolic Blood Pressure: >150 mmHg14
Week 24; Diastolic Blood Pressure: >90 mmHg26
Week 36; Systolic Blood Pressure: >150 mmHg02
Week 36; Diastolic Blood Pressure: >90 mmHg13
Week 36; Heart Rate: >100 bpm01
Week 52; Diastolic blood pressure: >90 mmHg21
Week 52; Heart Rate: >100 bpm01
Week 64; Systolic blood pressure: >150 mmHg12
Week 64; Diastolic blood pressure: >90 mmHg22
Week 64; Heart Rate: >100 bpm01
Week 76; Systolic blood pressure: >150 mmHg12
Week 76; Diastolic blood pressure: >90 mmHg21
Week 88; Systolic blood pressure: >150 mmHg01
Week 88; Diastolic blood pressure: >90 mmHg10
Week 88; Heart Rate: >100 bpm01
SecondaryPercentage of Participants With Clinical Remission by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4

Clinical remission was considered as CDAI score \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

Time frame:
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Percentage of participantsSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Week 1271.7 (57.7 to 83.2)64.9 (51.1 to 77.1)
Week 2475.9 (62.8 to 86.1)62.1 (48.4 to 74.5)
Week 3672.5 (56.1 to 85.4)60.5 (44.4 to 75.0)
Week 5265.6 (46.8 to 81.4)62.1 (42.3 to 79.3)
Week 6460.0 (36.1 to 80.9)73.7 (48.8 to 90.9)
Week 7668.4 (43.4 to 87.4)62.5 (35.4 to 84.8)
Week 8876.9 (46.2 to 95.0)71.4 (41.9 to 91.6)
Week 10477.8 (40.0 to 97.2)66.7 (38.4 to 88.2)
SecondaryPercentage of Participants With Clinical Response by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4

Clinical Response was defined as having clinical remission CDAI or \>=100-point decrease from baseline in CDAI score where, clinical remission was considered as CDAI \<150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores\*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.

Time frame:
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Response by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Percentage of participantsSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Week 1284.9 (72.4 to 93.3)78.9 (66.1 to 88.6)
Week 2486.2 (74.6 to 93.9)77.6 (64.7 to 87.5)
Week 3682.5 (67.2 to 92.7)81.4 (66.6 to 91.6)
Week 5278.1 (60.0 to 90.7)86.2 (68.3 to 96.1)
Week 6480.0 (56.3 to 94.3)84.2 (60.4 to 96.6)
Week 7678.9 (54.4 to 93.9)81.3 (54.4 to 96.0)
Week 8884.6 (54.6 to 98.1)92.9 (66.1 to 99.8)
Week 10477.8 (40.0 to 97.2)80.0 (51.9 to 95.7)
SecondaryPercentage of Participants With Clinical Remission by PRO2 at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4

Clinical remission was defined as PRO2 score \<8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores\*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.

Time frame:
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission by PRO2 at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Percentage of participantsSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Week 1260.4 (46.0 to 73.5)40.4 (27.6 to 54.2)
Week 2463.8 (50.1 to 76.0)43.1 (30.2 to 56.8)
Week 3662.5 (45.8 to 77.3)53.5 (37.7 to 68.8)
Week 5259.4 (40.6 to 76.3)48.3 (29.4 to 67.5)
Week 6450.0 (27.2 to 72.8)57.9 (33.5 to 79.7)
Week 7647.4 (24.4 to 71.1)50.0 (24.7 to 75.3)
Week 8869.2 (38.6 to 90.9)64.3 (35.1 to 87.2)
Week 10444.4 (13.7 to 78.8)53.3 (26.6 to 78.7)

Adverse events

Collected over AEs: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: SSA= 82.1 weeks, SS1= 19.9 weeks, SS3= 38.0 weeks, SS4= 166.3 weeks; maximum follow-up: SSA= 86.1 weeks, SS1= 23.9 weeks, SS3= 42 weeks and SS4= 170.3 weeks); All-cause mortality: From randomization through end of the study (maximum of 170.3 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SSA: Placebo in Induction Period0/1 (0%)0/1 (0%)0/1 (0%)
SSA: Etrasimod 2 mg in Induction Period0/42 (0%)2/42 (4.8%)19/42 (45.2%)
SSA: Etrasimod 3 mg in Induction Period0/41 (0%)1/41 (2.4%)21/41 (51.2%)
SSA: Placebo in Induction Period/Etrasimod 3 mg in Extension Period0/1 (0%)1/1 (100%)0/1 (0%)
SSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension Period0/28 (0%)4/28 (14.3%)19/28 (67.9%)
SSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension Period0/2 (0%)1/2 (50%)2/2 (100%)
SSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension Period0/34 (0%)5/34 (14.7%)23/34 (67.6%)
SS1: Placebo in Induction Period0/100 (0%)6/100 (6%)45/100 (45%)
SS1: Etrasimod 2 mg in Induction Period0/98 (0%)11/98 (11.2%)40/98 (40.8%)
SS1: Etrasimod 3 mg in Induction Period0/97 (0%)9/97 (9.3%)34/97 (35.1%)
SS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction Period0/17 (0%)0/17 (0%)6/17 (35.3%)
SS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction Period0/18 (0%)2/18 (11.1%)9/18 (50%)
SS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction Period0/37 (0%)3/37 (8.1%)11/37 (29.7%)
SS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction Period0/36 (0%)3/36 (8.3%)6/36 (16.7%)
SS3 Responder Cohort: Placebo/Placebo0/47 (0%)2/47 (4.3%)31/47 (66%)
SS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mg0/38 (0%)4/38 (10.5%)24/38 (63.2%)
SS3 Responder Cohort: Etrasimod 2 mg/Placebo0/33 (0%)3/33 (9.1%)20/33 (60.6%)
SS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mg0/28 (0%)6/28 (21.4%)17/28 (60.7%)
SS3 Responder Cohort: Etrasimod 3 mg/Placebo0/35 (0%)4/35 (11.4%)15/35 (42.9%)
SS3 Non-responder Cohort: Etrasimod 2 mg0/38 (0%)5/38 (13.2%)17/38 (44.7%)
SS3 Non-responder Cohort: Etrasimod 3 mg0/23 (0%)4/23 (17.4%)11/23 (47.8%)
SS4: Etrasimod 2 mg1/72 (1.4%)10/72 (13.9%)43/72 (59.7%)
SS4: Etrasimod 3 mg0/71 (0%)8/71 (11.3%)36/71 (50.7%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
Peri-Rectal AbscessInfections and infestations0/10/420/411/10/280/20/340/1000/980/970/170/180/370/360/470/380/330/280/350/380/230/720/71
NephrolithiasisRenal and urinary disorders0/10/420/410/10/281/20/340/1000/980/970/170/180/370/360/470/380/330/280/350/380/230/721/71
Crohn's diseaseGastrointestinal disorders0/10/421/410/11/280/22/341/1004/983/970/171/181/372/361/470/382/331/283/353/380/232/721/71
MalnutritionMetabolism and nutrition disorders0/10/420/410/11/280/20/340/1001/980/970/171/180/370/360/470/380/330/280/350/380/230/720/71
Abdominal painGastrointestinal disorders0/10/420/410/10/280/21/340/1000/980/970/170/180/370/360/471/380/331/280/352/380/230/721/71
Abdominal abscessInfections and infestations0/10/420/410/10/280/20/340/1001/980/970/170/180/370/360/470/380/331/280/350/381/230/720/71
Acute kidney injuryRenal and urinary disorders0/10/420/410/10/280/20/340/1000/980/970/170/180/370/360/471/380/330/280/350/381/231/720/71
Clostridium difficile infectionInfections and infestations0/10/420/410/10/280/20/340/1000/980/970/170/180/370/360/470/380/330/280/350/381/231/720/71
PneumoniaInfections and infestations0/10/420/410/10/280/20/340/1000/980/970/170/180/370/360/470/380/330/280/350/381/230/720/71
COVID-19Infections and infestations0/10/420/410/11/280/21/340/1000/980/970/170/180/370/360/470/380/330/280/350/380/230/720/71
Most frequent other events
Showing 10 of 69
Most frequent other events
EventSSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSSA: Placebo in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extension PeriodSSA: Etrasimod 2 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSSA: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extension PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Placebo in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS1: Etrasimod 2 mg in Induction Period/Etrasimod 2 mg in Extended Induction PeriodSS1: Etrasimod 3 mg in Induction Period/Etrasimod 3 mg in Extended Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mg
ArthralgiaMusculoskeletal and connective tissue disorders0/14/428/410/13/281/24/343/1009/989/970/172/181/372/367/477/383/333/283/353/382/236/722/71
COVID-19Infections and infestations0/12/424/410/12/281/27/346/1001/984/970/171/182/370/361/472/382/331/283/350/383/230/720/71
NauseaGastrointestinal disorders0/14/421/410/10/281/22/348/1007/988/970/171/181/370/362/470/380/331/282/352/381/230/720/71
Abdominal painGastrointestinal disorders0/10/420/410/11/281/23/349/10013/981/970/170/183/371/364/473/382/332/285/356/382/236/723/71
DiarrhoeaGastrointestinal disorders0/10/420/410/10/281/21/340/1000/980/970/171/181/370/364/473/381/330/282/352/382/230/720/71
Abdominal tendernessGastrointestinal disorders0/10/420/410/10/281/20/340/1000/980/970/170/180/370/360/470/380/330/280/350/380/230/720/71
Clostridium difficile infectionInfections and infestations0/10/420/410/13/281/20/340/1000/980/970/170/180/370/361/471/380/333/281/350/380/234/723/71
DysmenorrhoeaReproductive system and breast disorders0/10/420/410/10/281/20/340/1000/980/970/170/180/370/360/470/380/330/280/350/380/230/720/71
Crohn's diseaseGastrointestinal disorders0/10/420/410/17/280/27/348/1004/983/971/172/180/370/368/475/385/333/282/359/381/238/729/71
HeadacheNervous system disorders0/15/428/410/13/280/26/348/1006/987/970/172/183/371/361/473/381/333/280/353/380/230/720/71

Baseline characteristics

Eligible participants who completed treatment and met the study specific criteria in SS1 entered SS3 and eligible participants from SS3 and SSA who completed at least 52 and 66 weeks of treatment, respectively entered SS4; hence, participants are not exclusive. To avoid risk of re-identification of participant, baseline measure data is not disclosed for reporting arm SSA: Placebo in Induction Period and reported under category-Not Disclosed.

Age, Customized
Age, Customized(Participants)SSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mgTotal
SSA — <=18 years000————————————0
SSA — Between 18 and 65 years04239————————————81
SSA — >=65 years002————————————2
SSA — Not Disclosed100————————————1
SS1 — <=18 years———000—————————0
SS1 — Between 18 and 65 years———959494—————————283
SS1 — >=65 years———543—————————12
SS1 — Not Disclosed———000—————————0
SS3 — <=18 years——————0000000——0
SS3 — Between 18 and 65 years——————45363328331512——202
SS3 — >=65 years——————2200200——6
SS3 — Not Disclosed——————0000000——0
SS4 — <=18 years—————————————000
SS4 — Between 18 and 65 years—————————————6867135
SS4 — >=65 years—————————————448
SS4 — Not Disclosed—————————————000
Sex/Gender, Customized
Sex/Gender, Customized(Participants)SSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mgTotal
SSA — Female02219————————————41
SSA — Male02022————————————42
SSA — Not Disclosed100————————————1
SS1 — Female———494846—————————143
SS1 — Male———515051—————————152
SS1 — Not Disclosed———000—————————0
SS3 — Female——————221717111955——96
SS3 — Male——————2521161716107——112
SS3 — Not Disclosed——————0000000——0
SS4 — Female—————————————432871
SS4 — Male—————————————294372
SS4 — Not Disclosed—————————————000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mgTotal
SSA — Hispanic or Latino041————————————5
SSA — Not Hispanic or Latino03638————————————74
SSA — Unknown or Not Reported022————————————4
SSA — Not Disclosed100————————————1
SS1 — Hispanic or Latino———2710—————————19
SS1 — Not Hispanic or Latino———938981—————————263
SS1 — Unknown or Not Reported———526—————————13
SS1 — Not Disclosed———000—————————0
SS3 — Hispanic or Latino——————0523500——15
SS3 — Not Hispanic or Latino——————45323024271512——185
SS3 — Unknown or Not Reported——————2111300——8
SS3 — Not Disclosed——————0000000——0
SS4 — Hispanic or Latino—————————————6410
SS4 — Not Hispanic or Latino—————————————6563128
SS4 — Unknown or Not Reported—————————————145
SS4 — Not Disclosed—————————————000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SSA: Placebo in Induction PeriodSSA: Etrasimod 2 mg in Induction PeriodSSA: Etrasimod 3 mg in Induction PeriodSS1: Placebo in Induction PeriodSS1: Etrasimod 2 mg in Induction PeriodSS1: Etrasimod 3 mg in Induction PeriodSS3 Responder Cohort: Placebo/PlaceboSS3 Responder Cohort: Etrasimod 2 mg/Etrasimod 2 mgSS3 Responder Cohort: Etrasimod 2 mg/PlaceboSS3 Responder Cohort: Etrasimod 3 mg/Etrasimod 3 mgSS3 Responder Cohort: Etrasimod 3 mg/PlaceboSS3 Non-responder Cohort: Etrasimod 2 mgSS3 Non-responder Cohort: Etrasimod 3 mgSS4: Etrasimod 2 mgSS4: Etrasimod 3 mgTotal
SSA — American Indian or Alaska Native000————————————0
SSA — Asian011————————————2
SSA — Native Hawaiian or Other Pacific Islander000————————————0
SSA — Black or African American013————————————4
SSA — White03834————————————72
SSA — More than one race000————————————0
SSA — Unknown or Not Reported023————————————5
SSA — Not Disclosed100————————————1
SS1 — American Indian or Alaska Native———011—————————2
SS1 — Asian———844—————————16
SS1 — Native Hawaiian or Other Pacific Islander———000—————————0
SS1 — Black or African American———212—————————5
SS1 — White———808781—————————248
SS1 — More than one race———000—————————0
SS1 — Unknown or Not Reported———1059—————————24
SS1 — Not Disclosed———000—————————0
SS3 — American Indian or Alaska Native——————0100100——2
SS3 — Asian——————5011112——11
SS3 — Native Hawaiian or Other Pacific Islander——————0000000——0
SS3 — Black or African American——————0020201——5
SS3 — White——————3936282527118——174
SS3 — More than one race——————0000000——0
SS3 — Unknown or Not Reported——————3122431——16
SS3 — Not Disclosed——————0000000——0
SS4 — American Indian or Alaska Native—————————————101
SS4 — Asian—————————————246
SS4 — Native Hawaiian or Other Pacific Islander—————————————000
SS4 — Black or African American—————————————011
SS4 — White—————————————6563128
SS4 — More than one race—————————————000
SS4 — Unknown or Not Reported—————————————437
SS4 — Not Disclosed—————————————000
08

Study locations

510 sites
  • Center for Digestive Health (Endoscopy Location)
    Dothan, Alabama 36301, United States
  • Digestive Health Specialists
    Dothan, Alabama 36301, United States
  • Dothan Eyecare-Dr. Brent McKinley (OCT Location)
    Dothan, Alabama 36301, United States
  • Pulmonary Associates (PFT Location)
    Dothan, Alabama 36301, United States
  • Flowers Hospital (Imaging Location)
    Dothan, Alabama 36305, United States
  • Digestive Health Specialists (Satellite Clinic Location)
    Mobile, Alabama 36608, United States
  • Premier Medical Group East (Opthalmology & Optometry Facility)
    Mobile, Alabama 36608, United States
  • Pulmonary Associates (Chest X-Ray & PFT Facility)
    Mobile, Alabama 36608, United States
  • Surgicare of Mobile (Endoscopy & Biopsy Facility)
    Mobile, Alabama 36608, United States
  • Arizona Retina Institute/ Phoenix Retina Associates(OCT)
    Peoria, Arizona 85381, United States
  • SimonMed Imaging (Imaging)
    Peoria, Arizona 85381, United States
  • Sun City Endoscopy Center (Endoscopy)
    Sun City, Arizona 85351, United States
  • Om Research LLC
    Apple Valley, California 92307, United States
  • Victor Valley Advanced Imaging
    Apple Valley, California 92307, United States
  • Koman Family Outpatient Pavilion (ENDO)
    La Jolla, California 92037, United States
  • Perlman Medical Offices
    La Jolla, California 92037, United States
  • UCSD Clinical and Translational Research Institute
    La Jolla, California 92037, United States
  • UCSD Health System (Endo/PFT/DLCO)
    La Jolla, California 92037, United States
  • UCSD lnvestigational Drug Service Pharmacy
    La Jolla, California 92037, United States
  • Shiley Eye Institute (OCT)
    La Jolla, California 92093, United States
  • A V Pediatrics, Allergy and Family Medicine - PFT
    Lancaster, California 93534, United States
  • Advanced Endoscopy and Pain Center - Colonoscopy
    Lancaster, California 93534, United States
  • Advanced Imaging Center - Chest X-Ray
    Lancaster, California 93534, United States
  • Antelope Valley Eye Care - Ophthalmologist
    Lancaster, California 93534, United States
  • AV Pediatrics Allergy and Family Medicine
    Lancaster, California 93534, United States
  • Jatinder S. Pruthi, MD FACG CPI
    Lancaster, California 93534, United States
  • OM Research LLC
    Lancaster, California 93534, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • Retina Consultants of Southern California
    Victorville, California 92392, United States
  • Physicians Surgery Center
    Victorville, California 92395, United States
  • Front Range Endoscopy Center
    Colorado Springs, Colorado 80903, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • Colorado Springs Pulmonary Consultants, PC
    Colorado Springs, Colorado 80909, United States
  • The Wright Eye Center (OCT Facility)
    Colorado Springs, Colorado 80909, United States
  • Colorado Springs Imaging (Ultrasound and MRE Location)
    Colorado Springs, Colorado 80919, United States
  • Xera Med Research
    Boca Raton, Florida 33487, United States
  • RecioMed Clinical Research Network, Inc
    Boynton Beach, Florida 33472, United States
  • Florida Advanced Gastroenterology Center - Rahman Nakshabendi MD and Imad Nakshabendi, MD
    Brandon, Florida 33511, United States
  • Bay Area Chest Physicians, P.A. (Pulmonary Function Test)
    Clearwater, Florida 33756, United States
  • West Coast Endoscopy Center (Endoscopy Procedures)
    Clearwater, Florida 33756, United States
  • Northwood Vision (Optical Coherence Tomography)
    Clearwater, Florida 33761, United States
  • Safety Harbor Surgery (Endoscopy Procedures)
    Clearwater, Florida 33761, United States
  • Gastro Florida (Regulatory Administrative Duties)
    Clearwater, Florida 33762, United States
  • Beraja Medical Institute (OCT)
    Coral Gables, Florida 33134, United States
  • Advanced Eye Center
    Hialeah, Florida 33012, United States
  • UF Health Imaging Center-Emerson (chest x-rays)
    Jacksonville, Florida 32207, United States
  • UF Health Laboratory Emerson (blood draws)
    Jacksonville, Florida 32207, United States
  • UF Health Jacksonville Respiratory Therapy (PFT and DLCO)
    Jacksonville, Florida 32209, United States
  • UF Health Jacksonville-Faculty Clinic (ileocolonoscopy and biopsy)
    Jacksonville, Florida 32209, United States
  • UF Health Opthalmology - Jacksonville (Ophthalmology with OCT)
    Jacksonville, Florida 32209, United States
  • UF Health Radiology-Jacksonville (chest x-rays)
    Jacksonville, Florida 32209, United States
  • Cisca Pulmonary & Critical Care (PFT Facility)
    Jacksonville, Florida 32216, United States
  • Nicolitz Eye Consultants (OCT Facility)
    Jacksonville, Florida 32216, United States
  • Borland-Groover Clinic (Endoscopy Facility)
    Jacksonville, Florida 32256, United States
  • Encore Borland-Groover Clinical Research
    Jacksonville, Florida 32256, United States
  • Jupiter Outpatient Surgery Center
    Jupiter, Florida 33458, United States
  • IHS Health, LLC
    Kissimmee, Florida 34741, United States
  • Lee Shettle Eye & Hearing (Ophthalmoscopy Only)
    Largo, Florida 33773, United States
  • Infinite Clinical Research
    Miami, Florida 33133, United States
  • Pulmonology Physicians of South Florida
    Miami, Florida 33133, United States
  • Reina Eye Care P.A.
    Miami, Florida 33133, United States
  • The Endoscopy Center (Endoscopy Procedure)
    Miami, Florida 33134, United States
  • La Salud Research Clinic Inc.
    Miami, Florida 33155, United States
  • Research Associates of South Florida
    Miami, Florida 33156, United States
  • South Florida Center for Endoscopy and Digestive Disease, LLC
    Miami, Florida 33156, United States
  • Juan Barrio, MD (PFT when needed)
    Miami, Florida 33173, United States
  • Anchor Medical Research, Llc
    Miami, Florida 33176, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Gulfshore Endoscopy Center
    Naples, Florida 34102, United States
  • Retina Consultants of Southwest Florida OCT only
    Naples, Florida 34103, United States
  • Lisette Delgado Sanchez, MD PFT only
    Naples, Florida 34109, United States
  • Pediatric & Adult Research Center
    Orlando, Florida 32825, United States
  • IMIC Inc.
    Palmetto Bay, Florida 33157, United States
  • IMIC Inc
    Palmetto Bay, Florida 33157, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Bardmoor GastroEnterology
    Seminole, Florida 33777, United States
  • Larkin Community Hospital (Endoscopy Procedure)
    South Miami, Florida 33143, United States
  • St. Petersburg Endoscopy Center (Endoscopy Procedures)
    St. Petersburg, Florida 33705, United States
  • Pasadena Center for Asthma and Lung Disorders (PFT and DLCO Only)
    St. Petersburg, Florida 33707, United States
  • Bay Area Endoscopy and Surgery Center (Endoscopy only)
    St. Petersburg, Florida 33709, United States
  • Theia Clinical Research, LLC
    St. Petersburg, Florida 33709, United States
  • Advanced Research Institute Inc.(IP and PFT)
    St. Petersburg, Florida 33710, United States
  • Absolute Surgical Specialist - Craig Amshel, MD
    Sun City Center, Florida 33573, United States
  • Lab - Processing/ Storage
    Tampa, Florida 33606, United States
  • USF Health South Tampa Center for Advanced Healthcare
    Tampa, Florida 33606, United States
  • GCP Clinical Research,LLC
    Tampa, Florida 33609, United States
  • LoCicero Medical Group
    Tampa, Florida 33609, United States
  • Newsome Eye Specialist (OCT Procedures Only)
    Tampa, Florida 33609, United States
  • South Tampa Surgery Center
    Tampa, Florida 33609, United States
  • USF Health Morsani Center For Advanced Healthcare
    Tampa, Florida 33612, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Peachtree Allergy and Asthma Clinic - Chest X-rays and PFTs
    Atlanta, Georgia 30309, United States
  • Ross Eyecare - Opthalmoscopy and OCT
    Atlanta, Georgia 30324, United States
  • Atlanta Gastroenterology Associates (endoscopy only)
    Atlanta, Georgia 30342, United States
  • Atlanta Gastroenterology Associates(IP only)
    Atlanta, Georgia 30342, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • GI Alliance
    Arlington Heights, Illinois 60005, United States
  • Northwest Endoscopy Center (Endoscopy)
    Arlington Heights, Illinois 60005, United States
  • GI Alliance (PFT)
    Gurnee, Illinois 60031, United States
  • Illinois Gastroenterology Group-Gurnee (Patients Seen; IP Delivered)
    Gurnee, Illinois 60031, United States

Showing the first 100 of 510 sites across 41 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dubinsky MC, Wu J, McDonnell A, Lazin K, Goetsch M, Branquinho D, Modesto I, Armuzzi A. Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program. J Crohns Colitis. 2025 May 8;19(5):jjae173. doi: 10.1093/ecco-jcc/jjae173. PubMed 39575597 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Apr 2025, 63 months.

Results were first posted in Jul 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2019
First posted
Nov 21, 2019
StartActual
Jan 6, 2020
Primary completionActual
Apr 23, 2025
CompletionActual
Jun 9, 2025
Results first posted
Jul 1, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04173273
Lead sponsor
Pfizer
Collaborators
Arena is a wholly owned subsidiary of Pfizer
Responsible party
Sponsor
First posted
Nov 21, 2019
Start date
Jan 6, 2020
Primary completion
Apr 23, 2025
Completion
Jun 9, 2025
Results posted
Jul 1, 2026
Last update
Jul 1, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion